Alterity Therapeutics (ATHE) Retained Earnings (2009 - 2026)

Alterity Therapeutics has reported Retained Earnings for 18 years, with the latest figure at -$174.2 million in Q2 2026.

• On a quarterly basis, Retained Earnings fell 20.42% year-over-year to -$174.2 million in Q2 2026; TTM through Jun 2026 was -$174.2 million, a 20.42% decrease from a year earlier, with the FY2026 full-year figure at -$174.2 million, down 177.12% from the prior year.
• Retained Earnings was -$174.2 million for Q2 2026 at Alterity Therapeutics, down from -$153.9 million in the prior quarter.
• The five-year high for Retained Earnings was $195.1 million in Q2 2023, with the low at -$174.2 million in Q2 2026.
• Average Retained Earnings over 5 years is -$105.5 million, with a median of -$141.1 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings sank 199.68% in 2022, then surged 249.78% in 2023.
• Over 5 years, Retained Earnings stood at -$124.4 million in 2022, then fell by 5.49% to -$131.3 million in 2023, then dropped by 10.11% to -$144.5 million in 2024, then dropped by 6.47% to -$153.9 million in 2025, then retreated by 13.2% to -$174.2 million in 2026.
• The last three Retained Earnings figures came in at -$174.2 million (Q2 2026), -$153.9 million (Q4 2025), and -$144.7 million (Q2 2025), per Business Quant data.